Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2025-01-17 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司关于2025年第一次临时股东大会（股东特别大会）股权登记日的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement regarding the record date for shareholders to be eligible to attend and vote at the 2025 first extraordinary general meeting (special shareholders meeting) of BeiGene Ltd. It specifies the share registration dates for different classes of shares across multiple stock exchanges and mentions that further details about the meeting will be disclosed later. The document does not contain any financial statements, management discussion, or detailed report content. It is a formal notice about the shareholder meeting's record date, which is a procedural announcement related to shareholder voting rights. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it pertains to shareholder voting eligibility and meeting arrangements rather than the meeting results or the meeting materials themselves. The document length is short (1874 characters), and it is not a report publication announcement or a regulatory filing. Hence, the best classification is DVA with high confidence.
2025-01-17 Chinese
百济神州有限公司自愿披露关于公司业务进展的公告
Capital/Financing Update Classification · 90% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. about its business progress, including a CEO presentation at the 43rd Annual J.P. Morgan Healthcare Conference. It contains forward-looking statements about expected profitability for the full year 2025 but explicitly states that the financial data are preliminary, unaudited, and not a formal financial report. The document is short (1137 characters) and does not contain actual financial statements or detailed financial analysis. It is an update on business progress and outlook rather than a formal earnings release or annual/interim report. It is not a transcript of the conference call but a summary announcement. Therefore, the best fitting category is Capital/Financing Update (CAP) as it relates to business progress and financial outlook disclosures, or possibly Investor Presentation (IP). However, since it is an announcement of business progress and financial outlook without detailed presentation slides, CAP is more appropriate. Confidence is high due to clear content and length.
2025-01-14 Chinese
港股公告：翌日披露报表
Transaction in Own Shares Classification · 95% confidence The document is a detailed disclosure report about changes in issued shares and treasury shares of a listed company, including share option exercises by directors and confirmations of compliance with listing rules. It references specific Hong Kong Stock Exchange Listing Rules (Main Board and GEM) related to share issuance and repurchase disclosures. The document is structured as a regulatory disclosure form (FF305) with multiple pages detailing share movements, confirmations, and compliance statements. It is not an annual or interim financial report, earnings release, or management discussion. It is not a proxy, AGM material, or legal proceeding. The content fits the category of a Transaction in Own Shares or share issuance disclosures. Given the detailed nature of share issuance and treasury share changes, this aligns best with the category "Transaction in Own Shares (POS)". The document length is about 4030 characters, which is substantive and not a mere announcement. Therefore, the classification is POS with high confidence.
2025-01-08 Chinese
美股公告：表格10-K/A
Annual Report Classification · 100% confidence The document is a Form 10-K/A, which is an amended annual report filed with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. It includes detailed financial statements, auditor's reports, management certifications under Sections 302 and 906 of the Sarbanes-Oxley Act, and other disclosures typical of an annual report. The presence of comprehensive financial data, auditor opinions, and management discussion confirms this is the actual amended annual report, not just an announcement or certification. Therefore, the document fits the category of an Annual Report (10-K). FY 2023
2025-01-08 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly securities movement report for a listed issuer, detailing changes in issued shares, share options, and other share-related transactions for the month ending December 31, 2024. It includes detailed tables of share capital changes, share issuance, stock options exercised, and confirmations related to compliance with listing rules. The document is submitted to the Hong Kong Stock Exchange and references specific listing rules (Chapter 19B, Main Board Listing Rules, GEM Listing Rules). It is not an annual or quarterly financial report, nor an earnings release or management discussion. It is a regulatory filing specifically reporting share capital and securities movements for the month, consistent with a Major Shareholding Notification or Share Issue/Capital Change report. Given the detailed monthly share capital changes and share option exercises, the best fit is Share Issue/Capital Change (SHA). The document length and content confirm it is the report itself, not just an announcement or certification, so it is not RPA or RNS.
2025-01-07 Chinese
港股公告：授出购股权及受限制股份单位
Remuneration Information Classification · 95% confidence The document is a detailed announcement regarding the grant of share options and restricted share units under the company's 2016 Option and Incentive Plan. It includes specifics such as grant dates, number of shares, exercise prices, vesting schedules, and the rationale for the grants. The document references compliance with listing rules and is issued by the company's board remuneration committee. It is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is also not a transcript, legal proceeding, or merger-related document. The content fits the category of Remuneration Information, as it details compensation-related equity awards to employees and service providers. The document length is 4129 characters, which is sufficient for a detailed remuneration disclosure rather than a brief announcement. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2025-01-07 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.